Compare CET & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | MNMD |
|---|---|---|
| Founded | 1929 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | CET | MNMD |
|---|---|---|
| Price | $50.85 | $13.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 38.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.40 | N/A |
| Revenue | ★ $27,062,484.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.85 | ★ N/A |
| Revenue Growth | ★ 15.78 | N/A |
| 52 Week Low | $40.24 | $4.70 |
| 52 Week High | $52.44 | $14.43 |
| Indicator | CET | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 57.40 |
| Support Level | $50.60 | $12.85 |
| Resistance Level | $51.31 | $13.54 |
| Average True Range (ATR) | 0.66 | 0.69 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 58.90 | 62.94 |
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).